Menu Search
Equities

Elicio Therapeutics Inc

9HA:BER

Elicio Therapeutics Inc

Actions
  • Price (EUR)4.70
  • Today's Change0.38 / 8.80%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:40 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Elicio Therapeutics Inc had revenues fall -100.00% from 2.30m to 0.00, though the company grew net income from a loss of 38.81m to a smaller loss of 35.20m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-144.89%
Return on equity-353.01%
Return on investment-202.49%
More ▼

Cash flow in USDView more

In 2023, Elicio Therapeutics Inc increased its cash reserves by 69.97%, or 5.89m. Cash Flow from Financing totalled 38.61m or -- of revenues. In addition the company used 32.69m for operations while cash used for investing totalled 32.00k.
Cash flow per share-4.38
Price/Cash flow per share--
Book value per share-0.161
Tangible book value per share-0.161
More ▼

Balance sheet in USDView more

Elicio Therapeutics Inc uses little or no debt in its capital structure.
Current ratio0.8819
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.